All In MedTech

Device Trial Radar · NCT03463395

Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux

Last checked: Nov 19, 2026Latest source record: May 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jul 2020

Primary completion

Nov 2021

Study completion Nov 2021

Sponsor

Lead sponsor
Medical College of WisconsinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 13, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

We hypothesize that tissue and salivary pepsin will resolve after 12 weeks use of Reza Band, but not following standard of care alone. Additionally, RFS, RSI and inflammatory cytokines (IL -1β, -6, and -8) will decrease to normative levels following 12 weeks use of Reza Band, but not with standard of care alone. Primary Objective The primary objective is to evaluate the efficacy of the Reza Band for the treatment of LPR. We propose a pilot clinical trial to test the hypothesis that the Reza Band is effective for the treatment of LPR, measured by resolution of pepsin and decrease to normative values for RSI, Reflux Finding Score (RFS) and inflammatory cytokines. The long-term goal is to determine the efficacy of the Reza Band in the sequential progression of reflux-attributed laryngeal inflammatory and neoplastic disease.

Conditions

  • Laryngopharyngeal Reflux

Interventions

  • Reza bandDevice

    Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Tissue and Salivary Pepsin LevelsTime frame: The change in Pepsin will be measured pre and post 12 week treatment for LPR +/- Reza band

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Froedtert Hospital and Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.